Peter Vickerman

TL;DR: A global multistage systematic review of sharing of equipment used for injecting drug use (IDU) identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa.

TL;DR: A consistently higher HCV prevalence in HIV-infected individuals than HIV-negative individuals across all risk groups and regions, but especially in PWID is noted, which highlights the importance of routine HCV testing in all HIV- infected individuals, butespecially in PWIDs.

TL;DR: Genital HSV-1 burden can be substantial but varies widely by region, and future control efforts, including development of HSV vaccines, should consider the epidemiology of HSv-1 in addition toHSV-2, and especially the relative contribution of HS V-1 to genital infection.

TL;DR: In this article, the authors projected the potential impact of interferon-free direct-acting antiviral (DAA) treatments on hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) in three settings.

TL;DR: Evidence on the effectiveness of individual-level approaches to prevention of HIV infection is summarized, global and regional coverage of opioid substitution treatment, needle and syringe programmes, and antiretroviral treatment is reviewed, and the effect of increased coverage and a combination of these three approaches on HIV transmission and prevalence in injecting drug users is modeled.